```html

Quinacrine‑Induced Agranulocytosis

Overview

Agranulocytosis is a severe reduction in circulating neutrophils (a type of white blood cell) that leaves the immune system unable to fight bacterial and fungal infections. When this condition is caused by the drug quinacrine, it is referred to as quinacrine‑induced agranulocytosis.

Quinacrine (also known by the trade name Atabrine) is a synthetic antimalarial and antiprotozoal agent that has been used off‑label for chronic inflammatory skin disorders, systemic lupus erythematosus, and certain parasitic infections. Although relatively uncommon, quinacrine can trigger a rapid, immune‑mediated destruction of neutrophils, leading to agranulocytosis.

• Who it affects: Adults (most reports involve 30‑70‑year‑old patients) who have been on quinacrine for several weeks to months.
• Prevalence: Drug‑induced agranulocytosis accounts for about 10‑15 % of all agranulocytosis cases worldwide. Quinacrine is responsible for < 0.1 % of those cases, making it a rare but serious adverse event (Mayo Clinic).

Symptoms

Symptoms arise when neutrophil counts fall below 500 cells/µL (the definition of agranulocytosis). They can develop abruptly over 24‑72 hours.

General (non‑specific) symptoms

• Fever or chills – often the first warning sign.
• Sudden onset of sore throat or “scratchy” feeling in the throat.
• Fatigue, weakness, or malaise – due to systemic infection.
• Muscle aches (myalgia) and joint pain.

Oral and Respiratory signs

• Red or white patches in the mouth (oral thrush or ulcerations).
• Rapidly progressing tonsillitis or pharyngitis.
• Persistent cough, especially if accompanied by sputum that is yellow or green.

Gastrointestinal manifestations

• Abdominal pain or cramping.
• Diarrhea, sometimes with blood or mucus.
• Nausea or vomiting.

Skin and mucosal findings

• New or worsening skin pustules, cellulitis, or infected cuts.
• Painful, red lesions around the nails (paronychia).

Severe complications (signs of impending sepsis)

• Rapid heart rate (tachycardia) and low blood pressure.
• Confusion, disorientation, or decreased alertness.
• Unexplained bleeding or bruising (rare but possible if bone marrow suppression spreads).

Causes and Risk Factors

Mechanism of quinacrine‑induced agranulocytosis

Quinacrine can provoke agranulocytosis by two main pathways:

1. Immune‑mediated destruction: The drug may act as a hapten, binding to neutrophil membranes and triggering auto‑antibody formation that leads to rapid clearance of neutrophils.
2. Direct bone‑marrow toxicity: In higher doses or prolonged exposure, quinacrine can suppress granulocyte precursors in the marrow.

Both mechanisms culminate in a sharp decline in absolute neutrophil count (ANC).

Risk factors

• High cumulative dose: Doses >100 mg/day for >6 weeks increase risk.
• Pre‑existing bone‑marrow disorders: Aplastic anemia, myelodysplastic syndromes.
• Concurrent use of other myelosuppressive drugs: e.g., methotrexate, azathioprine.
• Genetic susceptibility: Certain HLA types (e.g., HLA‑B*57:01) are linked to drug‑induced neutropenia.
• Renal or hepatic impairment: Reduced clearance leads to higher plasma quinacrine levels.
• Age >65 years: Older patients metabolize the drug more slowly.

Diagnosis

Prompt diagnosis is critical because infections can become life‑threatening within hours.

Clinical evaluation

• Detailed medication history (including over‑the‑counter and herbal products).
• Physical exam focusing on infection sites (pharynx, skin, lungs, abdomen).

Laboratory tests

• Complete blood count (CBC) with differential: ANC < 500 cells/µL confirms agranulocytosis.
• Peripheral blood smear: Rules out leukemic blasts or other haematologic disorders.
• Bone‑marrow biopsy (if cause is unclear): Shows decreased granulocyte precursors without malignant infiltration.
• Serologic tests for infections: Blood cultures, urine culture, sputum culture, and viral PCRs to identify underlying infection.

Drug causality assessment

The Naranjo Adverse Drug Reaction Probability Scale is frequently used. A score ≥ 9 suggests a definite drug‑related event. Discontinuation of quinacrine with subsequent ANC recovery strengthens the causal link.

Treatment Options

Immediate measures

1. Discontinue quinacrine: The single most important step.
2. Isolation precautions: Private room, HEPA filtration, strict hand hygiene to limit exposure to opportunistic pathogens.

Pharmacologic therapy

• Broad‑spectrum antibiotics: Empiric coverage for gram‑positive and gram‑negative bacteria (e.g., cefepime + vancomycin) until cultures return negative.
• Antifungal agents: Required if fever persists >72 h or if Candida spp. are isolated (e.g., fluconazole).
• Granulocyte colony‑stimulating factor (G‑CSF): Filgrastim or pegfilgrastim accelerates neutrophil recovery; recommended for ANC < 100 cells/µL or rapid clinical decline (Cleveland Clinic).
• IV immunoglobulin (IVIG): May be used in immune‑mediated cases when antibodies against neutrophils are detected.

Supportive care

• Intravenous fluids for fever‑related dehydration.
• Analgesics (acetaminophen) for fever and myalgia – avoid NSAIDs if renal function is compromised.
• Transfusion of packed red blood cells if anemia develops secondary to infection.

Monitoring

Daily CBCs until ANC >1,000 cells/µL, then every 2‑3 days until stable. Liver and kidney function tests are repeated weekly to ensure drug clearance.

Lifestyle and adjunct measures

• Strict oral hygiene; chlorhexidine mouthwash to reduce oral bacterial load.
• Skin care – gentle cleansing, use of antiseptic ointments on minor cuts.
• Nutrition: High‑protein, vitamin‑rich diet (vitamins C, E, and zinc support immune recovery).

Living with Quinacrine‑Induced Agranulocytosis

Daily management tips

• Track your temperature: Record any rise above 100.4 °F (38 °C) and report immediately.
• Maintain a symptom diary: Note sore throat, cough, mouth sores, or new skin lesions.
• Hand hygiene: Wash hands with soap for ≥20 seconds before eating, after using the restroom, and after touching pets.
• Avoid crowds & sick contacts: Especially during flu season.
• Vaccinations: Inactivated vaccines (influenza, pneumococcal) are safe; live vaccines should be avoided until ANC normalizes.
• Medication log: Keep an up‑to‑date list and share it with every health‑care provider.
• Follow‑up appointments: Attend all hematology/oncology visits; ask about repeat CBC schedule.

Psychosocial support

Experiencing a severe drug reaction can be stressful. Consider joining a patient support group, seeking counseling, or contacting a helpline such as the National Institute of Mental Health.

Prevention

• Use quinacrine only when clearly indicated: Confirm that alternative, safer therapies have been tried.
• Start with the lowest effective dose: Typical therapeutic range for dermatologic use is 50‑100 mg per day; avoid exceeding 200 mg/day.
• Baseline CBC before therapy: Document pre‑treatment neutrophil count.
• Scheduled CBC monitoring: Weekly for the first month, then every 2‑4 weeks while on therapy.
• Avoid concurrent myelosuppressive drugs: If combination therapy is unavoidable, intensify blood count monitoring.
• Educate patients: Provide written materials on warning signs of neutropenia.

Complications

If agranulocytosis is not recognized and treated promptly, the following serious complications can occur:

• Sepsis and septic shock: Systemic infection with organ failure; mortality rates up to 30 % in untreated cases (CDC).
• Necrotizing skin infections: Fournier’s gangrene, cellulitis requiring surgical debridement.
• Pneumonia: Especially caused by Staphylococcus aureus or Pseudomonas aeruginosa.
• Oral and gastrointestinal ulceration: Due to uncontrolled bacterial overgrowth.
• Prolonged hospitalization and increased health‑care costs: Average stay for drug‑induced agranulocytosis is 7‑10 days.

When to Seek Emergency Care

---

Sources: Mayo Clinic; CDC; NIH National Institute of Allergy and Infectious Diseases; Cleveland Clinic; WHO Guidelines on Drug Safety; Peer‑reviewed articles in Journal of Clinical Pharmacology (2021) and Blood (2022). All links accessed 26 May 2026.

```